Mytolac (Lanreotide Acetate)

Lanreotide acetate, the active ingredient in Mytolac, is a somatostatin analog presented as a sterile solution for subcutaneous use. It reduces excess growth hormone secretion in patients with acromegaly and inhibits hormone release from neuroendocrine tumors, helping to control disease progression.

GNH USA supplies Mytolac as a licensed, GDP‑compliant international pharmaceutical supplier, meeting EU quality standards and providing the product to hospitals, oncology centres, transplant units and pharmacies worldwide. Our distribution network ensures timely delivery and regulatory compliance across multiple regions.

Mytolac, a somatostatin analog, is used in endocrine and neuroendocrine disease pathways. - Acromegaly: lowers elevated growth hormone levels and can reduce pituitary tumor size. - Gastroenteropancreatic neuroendocrine tumors: controls hormone secretion and slows tumor progression. - Carcinoid syndrome associated with neuroendocrine tumors: alleviates flushing and diarrhea caused by excess peptide release.

Adverse reactions may occur with any medication and should be monitored by the prescribing clinician.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Diarrhea: loose stools occurring after administration. - Abdominal pain: cramping or discomfort in the abdomen. - Nausea: feeling of sickness without vomiting. - Hyperglycemia: elevated blood glucose levels. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Gallstones: formation of biliary calculi requiring medical attention. - Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain. - Severe hyperglycemia: markedly high blood glucose requiring intervention. - Allergic reactions: rash, itching, or anaphylaxis in rare cases. - Cardiac arrhythmia: irregular heart rhythm observed in susceptible patients.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor for potential complications. - Glucose monitoring: regularly check blood sugar as lanreotide may affect glycemic control. - Gallbladder assessment: evaluate for gallstones or biliary disease prior to treatment. - Pituitary tumor evaluation: assess tumor size and visual fields before and during therapy. - Renal function: adjust use in patients with significant renal impairment. - Hypersensitivity: avoid in individuals with known allergy to lanreotide or formulation components. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Cyclosporine: may increase lanreotide concentrations, risking toxicity. - Concurrent somatostatin analogs: additive hormonal suppression can lead to severe side effects. - Insulin or oral hypoglycemics: may require dose adjustments due to altered glucose metabolism.

Moderate Interactions (Monitor Closely): - Glucocorticoids: can exacerbate hyperglycemia when combined with lanreotide. - Dopamine agonists: may influence hormonal balance and require monitoring. - QT‑prolonging agents: combined use may increase risk of cardiac arrhythmias.